drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR T cells)
drug_description
Patient-derived CD4/CD8 T cells are collected, lentivirally transduced ex vivo to express a CD19-specific chimeric antigen receptor, expanded, and infused. CAR engagement of CD19 activates T-cell cytotoxicity, producing deep depletion of CD19+ B cells and their precursors to curb autoreactive B-cell activity and autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a CD19-specific chimeric antigen receptor; upon binding CD19 on B cells, CAR signaling activates T-cell cytotoxicity and cytokine release, leading to deep depletion of CD19+ B cells and their precursors, thereby suppressing autoreactive B-cell activity and autoantibody production.
drug_name
Autologous anti-CD19 CAR T-cell therapy
nct_id_drug_ref
NCT06347718